269 related articles for article (PubMed ID: 32891191)
21. The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
Rouphael NG; Paine M; Mosley R; Henry S; McAllister DV; Kalluri H; Pewin W; Frew PM; Yu T; Thornburg NJ; Kabbani S; Lai L; Vassilieva EV; Skountzou I; Compans RW; Mulligan MJ; Prausnitz MR;
Lancet; 2017 Aug; 390(10095):649-658. PubMed ID: 28666680
[TBL] [Abstract][Full Text] [Related]
22. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
23. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial.
Adegnika AA; de Vries SG; Zinsou FJ; Honkepehedji YJ; Dejon Agobé JC; Vodonou KG; Bikangui R; Bouyoukou Hounkpatin A; Bache EB; Massinga Loembe M; van Leeuwen R; Molemans M; Kremsner PG; Yazdanbakhsh M; Hotez PJ; Bottazzi ME; Li G; Bethony JM; Diemert DJ; Grobusch MP;
Lancet Infect Dis; 2021 Feb; 21(2):275-285. PubMed ID: 32926834
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.
Goepfert PA; Fu B; Chabanon AL; Bonaparte MI; Davis MG; Essink BJ; Frank I; Haney O; Janosczyk H; Keefer MC; Koutsoukos M; Kimmel MA; Masotti R; Savarino SJ; Schuerman L; Schwartz H; Sher LD; Smith J; Tavares-Da-Silva F; Gurunathan S; DiazGranados CA; de Bruyn G
Lancet Infect Dis; 2021 Sep; 21(9):1257-1270. PubMed ID: 33887209
[TBL] [Abstract][Full Text] [Related]
25. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
26. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial.
Zinsou JF; Diemert DJ; Dejon-Agobé JC; Adégbité BR; Honkpehedji YJ; Vodonou KG; Bikangui R; Edoa JR; Massinga Loembe M; Li G; Yazdanbakhsh M; Bottazzi ME; van Leeuwen R; Kremsner PG; Hotez PJ; Bethony JM; Grobusch MP; Adegnika AA
Lancet Infect Dis; 2024 Jul; 24(7):760-774. PubMed ID: 38513684
[TBL] [Abstract][Full Text] [Related]
28. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Stephenson KE; Wegmann F; Tomaka F; Walsh SR; Tan CS; Lavreys L; Ansel JL; Kanjilal DG; Jaegle K; Nkolola JP; Peter L; Fogel R; Bradshaw C; Tyler A; Makoni T; Howe L; Quijada D; Chandrashekar A; Bondzie EA; Borducchi EN; Yanosick KE; Hendriks J; Nijs S; Truyers C; Tolboom J; Zahn RC; Seaman MS; Alter G; Stieh DJ; Pau MG; Schuitemaker H; Barouch DH
Lancet HIV; 2020 Jun; 7(6):e410-e421. PubMed ID: 32078815
[TBL] [Abstract][Full Text] [Related]
29. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy.
Madhi SA; Koen A; Cutland CL; Jose L; Govender N; Wittke F; Olugbosi M; Sobanjo-Ter Meulen A; Baker S; Dull PM; Narasimhan V; Slobod K
Clin Infect Dis; 2017 Nov; 65(11):1897-1904. PubMed ID: 29029127
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.
Osorio JE; Velez ID; Thomson C; Lopez L; Jimenez A; Haller AA; Silengo S; Scott J; Boroughs KL; Stovall JL; Luy BE; Arguello J; Beatty ME; Santangelo J; Gordon GS; Huang CY; Stinchcomb DT
Lancet Infect Dis; 2014 Sep; 14(9):830-8. PubMed ID: 25087476
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
Ella R; Reddy S; Jogdand H; Sarangi V; Ganneru B; Prasad S; Das D; Raju D; Praturi U; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai S; Panda S; Abraham P; Gupta N; Ella K; Bhargava B; Vadrevu KM
Lancet Infect Dis; 2021 Jul; 21(7):950-961. PubMed ID: 33705727
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
34. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: an observer-blind, randomised, phase 1 trial.
Han HH; Diaz C; Acosta CJ; Liu M; Borkowski A
Lancet Infect Dis; 2021 Sep; 21(9):1282-1292. PubMed ID: 34019802
[TBL] [Abstract][Full Text] [Related]
35. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
Paoletti LC; Rench MA; Kasper DL; Molrine D; Ambrosino D; Baker CJ
Infect Immun; 2001 Nov; 69(11):6696-701. PubMed ID: 11598040
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
[TBL] [Abstract][Full Text] [Related]
37. Safety and Immunogenicity of a Second Dose of an Investigational Maternal Trivalent Group B Streptococcus Vaccine in Nonpregnant Women 4-6 Years After a First Dose: Results From a Phase 2 Trial.
Leroux-Roels G; Bebia Z; Maes C; Aerssens A; De Boever F; Grassano L; Buffi G; Margarit I; Karsten A; Cho S; Slobod K; Corsaro B; Henry O
Clin Infect Dis; 2020 Jun; 70(12):2570-2579. PubMed ID: 31394574
[TBL] [Abstract][Full Text] [Related]
38. Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial.
Platt HL; Bruno C; Buntinx E; Pelayo E; Garcia-Huidobro D; Barranco-Santana EA; Sjoberg F; Song JY; Grijalva CG; Orenstein WA; Morgan L; Fernsler D; Xu W; Waleed M; Li J; Buchwald UK;
Lancet Infect Dis; 2024 Jul; ():. PubMed ID: 38964361
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
40. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.
Chen WH; Neuzil KM; Boyce CR; Pasetti MF; Reymann MK; Martellet L; Hosken N; LaForce FM; Dhere RM; Pisal SS; Chaudhari A; Kulkarni PS; Borrow R; Findlow H; Brown V; McDonough ML; Dally L; Alderson MR
Lancet Infect Dis; 2018 Oct; 18(10):1088-1096. PubMed ID: 30120069
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
